To Identify Anytime Hyperglycaemia in Subjects With Normoglycaemia and Prediabetes
NCT05939895 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2024-02-20
Summary
To test these hypotheses, The Investigators will recruit 100 overweight and obese adolescents with HbA1c ranging across the ADA classification spectrum from normal to prediabetes,(nearly 40:normoglycemi, 30: IFG, 30:1GT) measure free-living glucose by continuous glucose monitoring (CGM), and assess the relationships among CGM outcomes, HbA1c, and OGTT results (FPG and 2-h glucose). Individual with overt diabetes will be excluded.
This will be a 2 visit study. Subjects will be coming to Fortis CDOC after a minimum 8-hour overnight fast. Informed written consent and validated questionnaire in a language known to them (English/Hindi) will be obtained from all participants.
Clinical details will be obtained from the case records of the patients. Note of visible markers of insulin resistance (acanthosis nigricans, buffalo hump, double chin, subcutaneous fat pads, skin) Anthropometry, skinfolds \& blood pressure will be recorded. Overweight and, obesity will be defined according to predefined guidelines for Asian Indian. Abdominal obesity is defined as waist circumference of ≥ 90 centimetres (cms) in males and ≥ 80 cms in females.
A blinded iPro Continuous Glucose Monitor (Medtronic MiniMed, Inc) will be inserted. After a calibration period of 1 hour, fasting laboratory result will be collected: FPG, HbA1c. HbA1c will be done by HPLC (NGSP approved, turbid inhibition immunoassay). Then subjects will consume 1.75 g/kg glucose, maximum 75 g (glucose beverage) and will have a second venepuncture 2 hours later for plasma glucose measurement.
While awaiting the 2-hour venepuncture, participants will be provided instructions on CGM device care and calibration. Participants will be instructed to wear the CGM device for a minimum of 72 hours and to not change any of their current dietary or activity habits for the period of CGM wear. They will be trained to use a glucose monitor and collect capillary blood glucose values at least three times daily, prior to meals. Participants will also be asked to complete a simple log of their activity, as well as record dietary intake, and sleep and wake times. The iPro and log-sheet will be returned in person after a minimum of 72 hours of recording time.
Investigators and patients will be kept blinded to CGM recordings throughout the study. Daily glycaemic variability will be assessed by the change in the mean amplitude of glucose excursions (MAGE) index, and through the standard deviation (SD) of the mean 24-hour blood glucose concentration. Day-to-day variability will be assessed through the mean of daily differences (MoDD in mg/dL). Daily glycaemic control will be assessed by the mean (M) daily CGM value, as well as by the times (in minutes/day) spent in optimal glycaemic range (70-140 mg/dL) and above predefined hyperglycaemic thresholds (140 ,180 and 200 mg/dL) together with the corresponding area under the curve (AUC) values.
In addition, areas under 24-hour glycaemic traces (AUCs) will be analysed to estimate: overall hyperglycaemia (defined asAUC≥100 mg/dL over the full 24-hour period = AUCtotal);postprandial hyperglycaemia (AUC\[0-4 h\], i.e. for four-hour periods after each of the main meals and, if considered relevant by the core laboratory, after additional snacks = AUCpp); and basal hyperglycaemia, i.e. overall hyperglycaemia - postprandial hyperglycaemia (AUCb)
Conditions
- Healthy
Interventions
- DEVICE
-
Medtronic G3 sensor
A Sensor is fitted on the arm and abdomen of every patient and using a CGMS App. the patient's blood glucose level are monitored at regular intervals.
Sponsors & Collaborators
-
National Diabetes Obesity and Cholesterol Foundation
collaborator OTHER -
Diabetes Foundation, India
lead OTHER
Principal Investigators
-
AMRITA GHOSH, MBBS · Fortis CDOC Hospital
Eligibility
- Min Age
- 30 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-01-01
- Primary Completion
- 2024-05-30
- Completion
- 2024-06-30
Countries
- India
Study Locations
More Related Trials
-
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
NCT03966911 ·Status: COMPLETED ·Phase: NA
-
Performance of the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
NCT03935191 ·Status: UNKNOWN
-
Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With Prediabetes
NCT05505565 ·Status: COMPLETED ·Phase: NA
-
Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data
NCT03028220 ·Status: COMPLETED ·Phase: NA
-
Time in Glucose Hospital Target
NCT05135676 ·Status: COMPLETED ·Phase: NA
-
Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial
NCT01788527 ·Status: COMPLETED ·Phase: NA
-
Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital
NCT05941286 ·Status: COMPLETED ·Phase: NA
-
Patterns and Glycaemic Endpoints for Diagnosing Gestational Diabetes
NCT05981547 ·Status: ACTIVE_NOT_RECRUITING
-
Dexcom G6 Intervention Study
NCT03877068 ·Status: COMPLETED ·Phase: NA
-
Continuous Glucose Monitoring for Various Degrees of Glucose Intolerance
NCT05491954 ·Status: UNKNOWN
-
Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes
NCT03020069 ·Status: COMPLETED ·Phase: NA
-
Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes
NCT02159638 ·Status: COMPLETED ·Phase: NA
-
A Study of Glycemic Control in Left Ventricular Assist
NCT05933161 ·Status: RECRUITING
-
Effect of CGM With Predictive Alarm on Hypoglycemia in Young Patients With T1D.
NCT05574023 ·Status: COMPLETED ·Phase: NA
-
Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in Kenya.
NCT05944731 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT)
NCT02232698 ·Status: COMPLETED ·Phase: NA
-
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
NCT04452396 ·Status: TERMINATED ·Phase: NA
-
PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor
NCT02154126 ·Status: COMPLETED ·Phase: NA
-
Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)
NCT00333853 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System
NCT07092761 ·Status: RECRUITING ·Phase: NA
-
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
NCT01341067 ·Status: COMPLETED
-
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
NCT04436822 ·Status: COMPLETED ·Phase: NA
-
The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes
NCT00994357 ·Status: COMPLETED ·Phase: NA
-
Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in South Africa
NCT05944718 ·Status: COMPLETED ·Phase: NA
-
BGM and HbA1c POC Device Evaluation
NCT06170515 ·Status: RECRUITING ·Phase: NA